Notable Analyst Rating Changes 10/14: CSC, GSK, SNY, ABX, CNO, HOG, TEL Upgrade; VLO, JBLU, AGCO Downgrade - Street Insider

Sign Up | Log In | What is SocialPicks?

Notable Analyst Rating Changes 10/14: CSC, GSK, SNY, ABX, CNO, HOG, TEL Upgrade; VLO, JBLU, AGCO Downgrade
Oct 14, 2009 03:03 PM UTC

Street Insider

Return	Risk
+10.66%	MID

Tracked Blogger

Profile & Performance

Subscribe to author

Symbol	Sentiment	Start	Return	Closed
HOG	n/a
ABX	n/a
CNO	n/a
TEL	n/a
SNY	n/a
CSC	n/a
GSK	n/a

Via StreetInsider.com News Articles:

UPGRADES:
Goldman Sachs upgraded Computer Sciences Corporation (NYSE: CSC) from Sell to Neutral and revised its 12-month price target from $46 to $54.

UBS upgrades GlaxoSmithKline (NYSE: GSK) to Buy.

UBS upgrades Sanofi-Aventis (NYSE: SNY) from Sell to Neutral.

J.P. Morgan upgrades Barrick Gold (NYSE: ABX) from Neutral to Overweight. Price target increased from $40 to $54.

FBR Capital upgrades Conseco Inc. (NYSE: CNO) to Outperform. Price target raised from $4 to $9.

Wells Fargo upgrades Harley-Davidson, Inc. (NYSE: HOG) to Outperform. Valuation range increased from $19-21 to $30-$32

Longbow Research upgrades Tyco Electronics (NYSE: TEL) from Neutral to Buy.

For daily real-time

Read the rest of original post »

Add Comment

Be the first to comment on this story and earn 2 points.

Your Comment

IN THE PRESS

None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.